Analysis of global trends in acute lymphoblastic leukemia in children aged 0-5 years from 1990 to 2021

1990年至2021年0-5岁儿童急性淋巴细胞白血病全球趋势分析

阅读:1

Abstract

BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with a significant global burden. This study evaluates global, regional, and national trends in the prevalence, mortality, and disability-adjusted life years (DALYs) of childhood ALL from 1990 to 2021, providing insights into disparities and progress across different socio-demographic and geographic contexts. METHODS: Data were sourced from the Global Burden of Disease study. Trends in prevalence, mortality, and DALYs were analyzed by socio-demographic index (SDI) regions, geographic areas, and countries. Estimated annual percentage changes (EAPCs) were used to quantify temporal trends. FINDINGS: Between 1990 and 2021, the global number of childhood ALL cases increased by 59.06%, reaching 168,879 cases in 2021, while ALL-related deaths and DALYs decreased by 66.71% and 66.13%, respectively. High- and high-middle SDI regions demonstrated significant improvements, driven by advances in healthcare and early diagnosis. In contrast, low-SDI regions faced persistent challenges, with a slight increase in DALYs observed in 2021. Geographic disparities were pronounced, with East Asia achieving the largest reductions in mortality and DALYs, whereas Sub-Saharan Africa and the Caribbean remained heavily burdened. INTERPRETATION: Despite progress in reducing mortality and DALYs globally, the rising prevalence of ALL and persistent disparities in low-SDI regions highlight the urgent need for equitable access to healthcare, early diagnosis, and effective treatment strategies. Strengthening healthcare infrastructure and fostering global collaboration are critical to further mitigating the burden of childhood ALL and ensuring equitable outcomes worldwide.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。